4.0
Apr 19, 2025
Recommend
CEO approval
Business Outlook
Pros
Incredible pay and benefits Incredibly smart community of scientists
Cons
My first 3 years were incredible in gRED (the R&D side of Genentech). However the last 3 years have been a series of reorganizations in gRED and the end is nowhere in sight. Layoffs occur regularly and are always looming. It's understandable that changes need to be made because many of our blockbuster drugs have lost exclusivity and we don't have replacements to generate the lost profits (many recent phase 3 failures). However the eternal reorg/layoff cycle is soul crushing after 3 years.